Exchange Session 4 – Implement/Sustain

Consider approaches to sustain MOUD and ensure continued access to high-quality care for our most challenged patients, including those who are pregnant, youth/adolescents, those with acute or chronic pain, and those electing to taper their dose.

Exchange Session 3 – Implement/Sustain

Review considerations for MOUD initiation and follow-up, including lab guidelines, and clinical management of patients with continued use (e.g., fentanyl, novel synthetic opioids), overdose risk, poly-substance use, and comorbid mental health conditions.

Exchange Session 2 – Prepare

Review patient screening considerations and discuss how OUD screening can be integrated into current clinic workflows. Discuss the training and certifications required for specific team members to implement MOUD. Highlight the critical role of Champions, and how to strategically select Champions to support MOUD implementation.

Exchange Session 1 – Explore

Have you considered treating patients with opioid use disorder (OUD) using Medications for Opioid Use Disorder (MOUD)? Have you wondered what is required to prescribe buprenorphine or other
pharmacotherapies? If you answered yes to either or both of these questions, this PCSS-MOUD Exchange session could provide you with the critical information and steps in determining the readiness of your site and clinical leadership. Initiating Medications for Opioid Use Disorder (MOUD) into your setting requires that you understand how pharmacotherapies work, including buprenorphine and its various formulations.

Overcoming Pharmacy Barriers to Buprenorphine Access

Target Audience: This activity was developed to meet the needs of physicians, nurses, pharmacists and interprofessional healthcare providers. Discussion is designed to promote interactivity through an informal “round table” conversation. Attendees will be given the opportunity to speak directly with the presenter to ask questions and discuss issues. In support of improving patient care, American […]